TRCT
CADX

Tower Research Capital (TRC)’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-162
Closed -$1K – 5479
2013
Q4 		$1K Sell
162
-294
-64% -$2.12K ﹤0.01% 4377
2013
Q3 		$3K Sell
456
-744
-62% -$4.73K ﹤0.01% 4049
2013
Q2 		$8K Buy
+1,200
New +$8.36K ﹤0.01% 2645

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tower Research Capital (TRC)'s CADX Position: Q1 2014 in Review

Tower Research Capital (TRC) sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 162 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $8K in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Tower Research Capital (TRC) reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 162 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Tower Research Capital (TRC)'s CADENCE PHARMACEUTICALS, INC COM STK position peaked at $8K in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2014, filed 2 May 2014.